SEARCH

SEARCH BY CITATION

References

  • Aull, M.J., Buell, J.F., Peddi, V.R., Trofe, J., Beebe, T.M., Hanaway, M.J., Roy-Chaudhury, P., Alloway, R.R., First, M.R., Woodle, E.S. & Israel Penn International Transplant Tumor Registry (2003) MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature. Transplantation, 75, 225228.
  • Aull, M.J., Buell, J.F., Trofe, J., First, M.R., Alloway, R.R., Hanaway, M.J., Wagoner, L., Gross, T., Beebe, T. & Woodle, E.S. (2004) Experience with 274 cardiac recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation, 78, 16761682.
  • Bates, W.D., Gray, D.W.R., Dada, M.A., Chetty, R., Gatter, K.C., Davies, D.R. & Morris, P.J. (2003) Lymphoproliferative disorders in Oxford renal transplant recipients. Journal of Clinical Pathology, 56, 439446.
  • Berney, T., Delis, S., Kato, T., Nishida, S., Mittal, N.K., Madariaga, J., Levi, D., Nery, J.R., Cirocco, R.E., Gelman, B., Ruiz, P. & Tzakis, A.G. (2002) Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation, 74, 10001006.
  • Birkeland, S., Hamilton-Dutoit, S. & Bendtzen, K. (2003) Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of post-transplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of re-transplantation. Transplantation, 75, 153158.
  • Blaes, A.H., Peterson, B.A., Bartlett, N., Dunn, D.L. & Morrison, V.A. (2005) Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer, 104, 16611667.
  • Buadi, F.K., Heyman, M.R., Gocke, C.D., Rapoport, A.P., Hakimian, R., Bartlett, S.T. & Sarkodee-Adoo, C. (2007) Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study. American Journal of Hematology, 82, 208214.
  • Buell, J.F., Gross, T.G., Hanaway, M.J., Trofe, J., Roy-Chaudhury, P., First, M.R. & Woodle, E.S. (2005) Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplantation Proceedings, 37, 954955.
  • Campbell, P. & Marcus, R. (2003) Monoclonal antibody therapy for lymphoma. Blood reviews, 17, 143152.
  • Carbone, P.P., Kaplan, H.S., Musshoff, K., Smithers, D.W. & Tubiana, M. (1971) Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Research, 31, 18601861.
  • Chapchap, P., Carone, F.E., Porta, G., Miura, I., Zerbini, M., Gayotto, L. & JG., M. (1991) Posttransplant lymphoproliferative disease of the liver successfully treated by retransplantation. Transplantation, 52, 736737.
  • Chau, I., Harries, M., Cunningham, D., Hill, M., Ross, P.J., Archer, C.D., Norman, A.R., Wotherspoon, A., Koh, D.M., Gill, K., Uzzell, M., Prior, Y. & Catovsky, D. (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin’s and non-Hodgkin’s lymphoma. British Journal of Haematology, 120, 970977.
  • Choquet, S., Leblond, V., Herbrecht, R., Socie, G., Stoppa, A.M., Vandenberghe, P., Fischer, A., Morschhauser, F., Salles, G., Feremans, W., Vilmer, E., Peraldi, M.N., Lang, P., Lebranchu, Y., Oksenhendler, E., Garnier, J.L., Lamy, T., Jaccard, A., Ferrant, A., Offner, F., Hermine, O., Moreau, A., Fafi-Kremer, S., Morand, P., Chatenoud, L., Berriot-Varoqueaux, N., Bergougnoux, L. & Milpied, N. (2006) Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood, 107, 30533057.
  • Choquet, S., Oertel, S., LeBlond, V., Riess, H., Varoqueaux, N., Dorken, B. & Trappe, R. (2007) Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Annals of Hematology, 86, 599607.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235242.
  • Comoli, P., Labirio, M., Basso, S., Baldanti, F., Grossi, P., Furione, M., Vigano, M., Fiocchi, R., Rossi, G., Ginevri, F., Gridelli, B., Moretta, A., Montagna, D., Locatelli, F., Gerna, G. & Maccario, R. (2002) Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood, 99, 25922598.
  • Cook, R.C., Connors, J.M., Gascoyne, R.D., Fradet, G. & Levy, R.D. (1999) Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet, 354, 16981699.
  • Davis, C. (2001) Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder. Transplation and Infectious Disease, 3, 108118.
  • Davis, C., Wood, B., Sabath, D., Joseph, J., Stehman-Breen, C. & Broudy, V. (1987) Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation, 66, 17701779.
  • Delone, P., Corkill, J., Jordan, M., Krapiva, P., Ghasemian, R., Sasaki, T. & Light, J. (1995) Successful treatment of Epstein-Barr virus infection with ganciclovir and cytomegalovirus hyperimmune globulin following kidney transplantation. Transplantation Proceedings, 27, 5859.
  • Demircin, G. & Rees, L. (1997) Retransplantation after post-transplant lymphoproliferative disease. Pediatric Nephrology, 11, 358360.
  • Diehl, V., Stein, H., Hummel, M., Zollinger, R. & Connors, J.M. (2003) Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology, 2003, 225247.
  • Dotti, G., Rambaldi, A., Fiocchi, R., Motta, T., Torre, G., Viero, P., Gridelli, B. & Barbui, T. (2001) Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica, 86, 618623.
  • Dotti, G., Fiocchi, R., Motta, T., Mammana, C., Gotti, E., Riva, S., Cornelli, P., Gridelli, B., Viero, P., Oldani, E., Ferrazzi, P., Remuzzi, G., Barbui, T. & Rambaldi, A. (2002) Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation, 74, 10951102.
  • Douglas, R.S., Goldstein, S.M., Katowitz, J.A., Gausas, R.E., Ibarra, M.S., Tsai, D., Sharma, A. & Nichols, C. (2002) Orbital presentation of posttransplantation lymphoproliferative disorder: a small case series. Opthalmology, 109, 23512355.
  • EBPG Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrology Dialysis Transplantation, 17, 3133, 35–36.
  • Elstrom, R.L., Andreadis, C., Aqui, N.A., Ahya, V.N., Bloom, R.D., Brozena, S.C., Olthoff, K.M., Schuster, S.J., Nasta, S.D., Stadtmauer, E.A. & Tsai, D.E. (2006) Treatment of PTLD with rituximab or chemotherapy. American Journal of Transplantation, 6, 569576.
  • Ferreri, A.J.M., Reni, M., Foppoli, M., Martelli, M., Pangalis, G.A., Frezzato, M., Cabras, M.G., Fabbri, A., Corazzelli, G., Ilariucci, F., Rossi, G., Soffietti, R., Stelitano, C., Vallisa, D., Zaja, F., Zoppegno, L., Aondio, G.M., Avvisati, G., Balzarotti, M., Brandes, A.A., Fajardo, J., Gomez, H., Guarini, A., Pinotti, G., Rigacci, L., Uhlmann, C., Picozzi, P., Vezzulli, P., Ponzoni, M., Zucca, E., Caligaris-Cappio, F. & Cavalli, F. (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. The Lancet, 374, 15121520.
  • Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. Journal of Clinical Oncology, 23, 41174126.
  • Fohrer, C., Caillard, S., Koumarianou, A., Ellero, B., Woehl-Jaegle, M.L., Meyer, C., Epailly, E., Chenard, M.P., Lioure, B., Natarajan-Ame, S., Maloisel, F., Lutun, P., Kessler, R., Moulin, B., Bergerat, J.P., Wolf, P. & Herbrecht, R. (2006) Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. British Journal of Haematology, 134, 602612.
  • Foroncewicz, B., Mucha, K., Usiekniewicz, J., Chmura, A., Kryst, P., Sołdacki, D. & Paczek, L. (2006) Posttransplant lymphoproliferative disorder of the lung in a renal transplant recipient treated successfully with surgery. Transplantation Proceedings, 38, 173176.
  • Ghobrial, I.M., Habermann, T.M., Maurer, M.J., Geyer, S.M., Ristow, K.M., Larson, T.S., Walker, R.C., Ansell, S.M., Macon, W.R., Gores, G.G., Stegall, M.D. & McGregor, C.G. (2005) Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders. Journal of Clinical Oncology, 23, 75747582.
  • Girinsky, T., Benhamou, E., Bourhis, J.-H., Dhermain, F., Guillot-Valls, D., Ganansia, V., Luboinski, M., Perez, A., Cosset, J.M., Socie, G., Baume, D., Bouaouina, N., Briot, E., Beaudre, A., Bridier, A. & Pico, J.L. (2000) Prospective Randomized Comparison of Single-Dose Versus Hyperfractionated Total-Body Irradiation in Patients With Hematologic Malignancies. Journal of Clinical Oncology, 18, 981986.
  • Gross, T.G., Bucuvalas, J.C., Park, J.R., Greiner, T.C., Hinrich, S.H., Kaufman, S.S., Langnas, A.N., McDonald, R.A., Ryckman, F.C., Shaw, B.W., Sudan, D.L. & Lynch, J.C. (2005) Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. Journal of Clinical Oncology, 23, 64816488.
  • Haque, T., Wilkie, G.M., Taylor, C., Amlot, P.L., Murad, P., Iley, A., Dombagoda, D., Britton, K.M., Swerdlow, A.J. & Crawford, D.H. (2002) Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet, 360, 436441.
  • Haque, T., Wilkie, G.M., Jones, M.M., Higgins, C.D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C., Amlot, P.L., Kelly, D., MacGilchrist, A., Gandhi, M.K., Swerdlow, A.J. & Crawford, D.H. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood, 110, 11231131.
  • Heim-Duthoy, K., Chitwood, K., Tortorice, K., Massy, Z. & Kasiske, B. (1994) Elective cyclosporine withdrawal 1 year after renal transplantation. American Journal of Kidney Diseases, 24, 846853.
  • Hsi, E.D., Singleton, T.P., Swinnen, L., Dunphy, C.H. & Alkan, S. (2000) Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients. American Journal of Surgical Pathology, 24, 100106.
  • Hsu, Y.C., Liao, W.C., Wang, H.P., Yao, M. & Lin, J.T. (2009) Catastrophic gastrointestinal manifestations of post-transplant lymphoproliferative disorder. Digestive and Liver Disease, 41, 238241.
  • Jaeger, G., Linkesch, W., Temmel, W. & Neumeister, P. (2005) Anti CD20 monoclonal antibody-based radioimmunotherapy of relapsed chemoresistant aggressive posttransplant B-lymphoproliferative disorder in heart-transplant recipients. Lancet Oncology, 6, 629631.
  • Jain, A.B., Marcos, A., Pokharna, R., Shapiro, R., Fontes, P.A., Marsh, W., Mohanka, R. & Fung, J.J. (2005) Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation, 80, 16921698.
  • Jenkins, D., DiFrancesco, L., Chaudhry, A., Morris, D., Glück, S., Jones, A., Woodman, R., Brown, C., Russell, J. & Stewart, D. (2002) Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients. Bone Marrow Transplantation, 30, 321326.
  • Johnson, S., Cherikh, W., Kauffman, H., Pavlakis, M. & Hanto, D. (2006) Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. American Journal of Transplantation, 6, 27432749.
  • Kang, S.K., Kirkpatrick, J.P. & Halperin, E.C. (2004) Low-dose radiation for posttransplant lymphoproliferative disorder. American Journal of Clinical Oncology, 26, 210214.
  • Karras, A., Thervet, E., Le Meur, Y., Baudet-Bonneville, V., Kessler, M. & Legendre, C. (2004) Successful renal retransplantation after post-transplant lymphoproliferative disease. American Journal of Transplantation, 4, 19041909.
  • Kollmar, O., Becker, S., Schilling, M.K. & Maurer, C.A. (2002) Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy. Transplantation, 73, 669670.
  • Kwong, Y.L. (2005) Natural-killer cell malignancies: diagnosis and management. Leukaemia, 19, 21862194.
  • Kwong, Y.L., Lam, C.C.K. & Chan, T.M. (2000) Post-transplantation lymphoproliferative disease of natural killer cell lineage: a clinicopathological and molecular analysis. British Journal of Haematology, 110, 197202.
  • Leblond, V., Sutton, L., Dorent, R., Davi, F., Bitker, M.O., Gabarre, J., Charlotte, F., Ghoussoub, J.J., Fourcade, C. & Fischer, A. (1995) Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. Journal of Clinical Oncology, 13, 961968.
  • Leblond, V., Dhedin, N., Bruneel, M.-F.M., Choquet, S., Hermine, O., Porcher, R., Quoc, S.N., Davi, F., Charlotte, F., Dorent, R., Barrou, B., Vernant, J.-P., Raphael, M. & Levy, V. (2001) Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders. Journal of Clinical Oncology, 19, 772778.
  • Libertiny, G., Watson, C.J., Gray, D.W., Welsh, K.I. & Morris, P.J. (2001) Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. British Journal of Surgery, 88, 13301334.
  • Little, R., Pittaluga, S., Grant, N., Steinberg, S., Kavlick, M., Mitsuya, H., Franchini, G., Gutierrez, M., Raffeld, M., Jaffe, E., Shearer, G., Yarchoan, R. & Wilson, W. (2003) Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood, 101, 46534659.
  • Marcus, R., Hodson, D., Coupland, S., Bessell, E., Mead, B. & Pettitt, A.R. (2007) Guidelines on the diagnosis and management of adult patients with primary CNS lymphoma (PCNSL) and primary intra-ocular lymphoma (PIOL). WWW document. URL http://www.bcshguidelines.com/pdf/PCNSL_guidelines.pdf.
  • Mead, G., Barrans, S., Qian, W., Walewski, J., Radford, J., Wolf, M., Clawson, S., Stenning, S., Yule, C. & Jack, A. (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood, 112, 22482260.
  • Mentzer, S.J., Fingeroth, J., Reilly, J.J., Perrine, S.P. & Faller, D.V. (1998) Arginine Butyrate-Induced Susceptibility to Ganciclovir in an Epstein-Barr-Virus-Associated Lymphoma. Blood Cells, Molecules, and Diseases, 24, 114123.
  • Milpied, N., Vasseur, B., Parquet, N., Garnier, J.L., Antoine, C., Quartier, P., Carret, A.S., Bouscary, D., Faye, A., Bourbigot, B., Reguerre, Y., Stoppa, A.M., Bourquard, P., Hurault de Ligny, B., Dubief, F., Mathieu-Boue, A. & Leblond, V. (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Annals of Oncology, 11(Suppl 1), 113116.
  • Nabors, L.B., Palmer, C.A., Julian, B.A., Przekwas, A.M. & Kew, C.E. (2009) Isolated Central Nervous System Posttransplant Lymphoproliferative Disorder Treated with High-Dose Intravenous Methotrexate. American Journal of Transplantation, 9, 12431248.
  • Oertel, S.H., Anagnostopoulos, I., Bechstein, W.O., Liehr, H. & Riess, H.B. (2000) Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Transplantation, 69, 430432.
  • Oertel, S., Papp-Váry, M., Anagnostopoulos, I., Hummel, M., Jonas, S. & Riess, H. (2003) Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. British Journal of Haematology, 123, 830835.
  • Oertel, S.H., Verschuuren, E., Reinke, P., Zeidler, K., Papp-Vary, M., Babel, N., Trappe, R.U., Jonas, S., Hummel, M., Anagnostopoulos, I., Dorken, B. & Riess, H.B. (2005) Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). American Journal of Transplantation, 5, 29012906.
  • Orjuela, M., Gross, T.G., Cheung, Y.K., Alobeid, B., Morris, E. & Cairo, M.S. (2003) A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clinical Cancer Research, 9, 3945S3952S.
  • Paranjothi, S., Yusen, R.D., Kraus, M.D., Lynch, J.P., Patterson, G.A. & Trulock, E.P. (2001) Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. Journal of Heart and Lung Transplantation, 20, 10541063.
  • Parker, A., Amlot, P., Bowles, K., Bradley, J.A., Emery, V., Featherstone, C., Gupte, G., Marcus, R., Parameshwar, J., Ramsay, A. & Newstead, C. (2009) Guidelines on the Surveillance, Diagnosis and Management of Post-Transplant Lymphoproliferative Disorders in Adult Solid Organ Transplant Recipients. WWW document. URL. http://www.bcshguidelines.com/pdf/pltd_finaldraft_071009.pdf.
  • Paya, C.V., Fung, J.J., Nalesnik, M.A., Kieff, E., Green, M., Gores, G., Habermann, T.M., Wiesner, R.H., Swinnen, L.J., Woodle, E.S., Bromberg, J.S. & for the ASTS/ASTP EBV-PTLD Task Force the Mayo Clinic organized International Consensus Development Meeting on Epstein Barr Virus-Induced Posttransplant Lymphoproliferative Disorders (PTLD) (1999) Epstein-Barr Virus-Induced Posttransplant Lymphoproliferative Disorders. Transplantation, 68, 15171525.
  • Penn, I. & Porat, G. (1995) Central nervous system lymphomas in organ allograft recipients. Transplantation, 59, 240244.
  • Perrine, S.P., Hermine, O., Small, T., Suarez, F., O’Reilly, R., Boulad, F., Fingeroth, J., Askin, M., Levy, A., Mentzer, S.J., Di Nicola, M., Gianni, A.M., Klein, C., Horwitz, S. & Faller, D.V. (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood, 109, 25712578.
  • Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trümper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A. & Loeffler, M. (2008) German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncology, 9, 105116.
  • Pham, P.T., Wilkinson, A.H., Gritsch, H.A., Pham, P.C., Miller, J.M., Lassman, C.R. & Danovitch, G.M. (2002) Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease. Transplantation Proceedings, 34, 11781181.
  • Pirsch, J., Stratta, R., Sollinger, H., Hafez, G., D’Alessandro, A., Kalayoglu, M. & Belzer, F. (1989) Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. American Journal of Medicine, 86, 241244.
  • Raj, R. & Frost, A. (2005) Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. Journal of Heart and Lung Transplantation, 24, 671679.
  • Reams, B.D., McAdams, H.P., Howell, D.N., Steele, M.P., Davis, R.D. & Palmer, S.M. (2003) Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest, 124, 12421249.
  • Savoldo, B., Goss, J.A., Hammer, M.M., Zhang, L., Lopez, T., Gee, A.P., Lin, Y.-F., Quiros-Tejeira, R.E., Reinke, P., Schubert, S., Gottschalk, S., Finegold, M.J., Brenner, M.K., Rooney, C.M. & Heslop, H.E. (2006) Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood, 108, 29422949.
  • Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., Bennett, C.L., Cantor, S.B., Crawford, J., Cross, S.J., Demetri, G., Desch, C.E., Pizzo, P.A., Schiffer, C.A., Schwartzberg, L., Somerfield, M.R., Somlo, G., Wade, J.C., Wade, J.L., Winn, R.J., Wozniak, A.J. & Wolff, A.C. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology, 24, 31873205.
  • Stephan, J.L., Le Deist, F., Blanche, S., Le Bidois, J., Peuchmaur, M., Lellouch-Tubiana, A., Hirn, M., Griscelli, C. & Fischer, A. (1992) Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody. Transplantation, 54, 246249.
  • Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (eds.) (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon.
  • Swinnen, L.J. (2001) Organ transplant-related lymphoma. Current Treatment Options in Oncology, 2, 301308.
  • Swinnen, L., Leblanc, M., Grogan, T., Gordon, L., Stiff, P., Miller, A., Kasamon, Y., Miller, T. & Fisher, R. (2008) Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation, 86, 215222.
  • Taj, M.M., Messahel, B., Mycroft, J., Pritchard-Jones, K., Baker, A., Height, S., Hadzic, N. & Pinkerton, C.R. (2008) Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. British Journal of Haematology, 140, 191196.
  • Taylor, A., Marcus, R. & Bradley, J. (2005) Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Critical Reviews in Oncology and Hematology, 56, 155.
  • Taylor, A.L., Bowles, K.M., Callaghan, C.J., Wimperis, J.Z., Grant, J.W., Marcus, R.E. & Bradley, J.A. (2006) Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation, 82, 375381.
  • Trappe, R.U., Choquet, S., Reinke, P., Dreyling, M., Mergenthaler, H.G., Jager, U., Kebelmann-Betzing, C., Jonas, S., Lehmkuhl, H., Anagnostopoulos, I., Leblond, V., Hetzer, R., Dorken, B., Riess, H. & Oertel, S. (2007) Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab. Transplantation, 84, 17081712.
  • Tsai, D., Hardy, C., Tomaszewski, J., Kotloff, R., Oltoff, K., Somer, B., Schuster, S., Porter, D., Montone, K. & Stadtmauer, E. (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation, 71, 10761088.
  • Tulpule, S., Mikhael, G., Kazmi, M., Nunan, T., Van Der Walt, J., Goldsmith, D. & Fields, P. (2005) B Cell Post Transplant Lymphoproliferative Disorder Complicating Solid Organ Transplantation (B-PTLD):a Single Centre Review Reporting 1) Results with Chemo-Immunotherapy (CHOP/R) and 2) the Predictive Ability of FDG-PET Scanning To Correlate with Long Term Overall Survival. Blood (ASH Annual Meeting Abstracts), 106, 1500.
  • Vose, J.M., Bierman, P.J., Anderson, J.R., Weisenburger, D., Moravec, D.F., Sorensen, S., Hutchins, M., Dowling, M.D., Howe, D. & Okerbloom, J. (1991) CHLVPP chemotherapy with involved-field irradiation for Hodgkin’s disease: favorable results with acceptable toxicity. Journal of Clinical Oncology, 9, 14211425.
  • Webber, S.A. & Naftel, D.C. (2006) Pediatric heart transplant study. Lymphoproliferative disorders after pediatric heart transplantation: a multi-institutional study. Lancet, 367, 233239.
  • Williams, S.L., Hartline, C.B., Kushner, N.L., Harden, E.A., Bidanset, D.J., Drach, J.C., Townsend, L.B., Underwood, M.R., Biron, K.K. & Kern, E.R. (2003) In Vitro Activities of Benzimidazole D- and L-Ribonucleosides against Herpesviruses. Antimicrobial Agents and Chemotherapy, 47, 21862192.
  • Wilson, W., Grossbard, M., Pittaluga, S., Cole, D., Pearson, D., Drbohlav, N., Steinberg, S., Little, R., Janik, J., Gutierrez, M., Raffeld, M., Staudt, L., Cheson, B., Longo, D., Harris, N., Jaffe, E., Chabner, B., Wittes, R. & Balis, F. (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood, 99, 26852693.
  • Wotherspoon, A., Diss, T., Pan, L., Singh, N., Whelan, J. & Isaacson, P. (1996) Low grade gastric B-cell lymphoma of mucosa associated lymphoid tissue in immunocompromised patients. Histopathology, 28, 129134.
  • Zilz, N.D., Olson, L.J. & McGregor, C.G. (2001) Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. Journal of Heart and Lung Transplantation, 20, 770772.